The companies owned by the Tudorache family, who control Montero pharmaceutical group, consolidated under investment vehicle Newarch Investments, are expected to generate revenues worth 150m euros this year, with the largest contribution (100m euros) coming from the pharmaceutical distribution unit.
"The growth rate must amount to at least 30% with regard to organic growth. Nevertheless, we are counting on acquisitions for all companies within the group," said Radu Tudorache, one of Montero's shareholders.
For Montero, for instance, talks are underway for a merger or acquisition, which would double next year's turnover to 200m euros, from 100m euros this year.
"Expansion will be financed through bank loans. For distribution, we are in talks for a 40m-euro loan with several banks," added Radu Tudorache.
The first step outside Romania along this segment is also planned for 2008. Newarch Investments is present abroad only through Montero Soft, which owns PharmEc Software brand. The company also operates in Macedonia and plans to expand in other states in this region.
Montero Soft's turnover is expected to reach 2.5m euros this year and 3.3m euros next year. Newarch Investments includes 15 businesses with activities in pharmaceuticals and also real estate, which are structured into two business units.
Another company part of Newarch, Metropola Imobiliare, is involved, together with Icelandic company Askar Capital, in a project estimated to be worth 500m euros.
Radu Tudorache believes the new structure will allow the company to become a regional player. The first step in this regard has already been made when the Tudorache family took control of distributor Montero from Slovenia's Monteko company.
The Tudorache family took over 38% of Montero stock from Monteko, and now holds a 76% stake. The acquisition was operated through
